Clinical Trial Update: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating PEG-ASP+Gemox and thalidomide for Extranodal NK/T-Cell Lymphoma, Nasal and Nasal-Type; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk-t-cell Lymphoma Nasal and Nasal-type

Drugs mentioned

• PEG-ASP+Gemox regimen
• Thalidomide (thalidomide)

Snippet

Sponsor: Huiqiang Huang | Conditions: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | Phase 3 | Status: UNKNOWN